BR112013001244A2 - ésteres de ácido de piridin-2-il sulfanila e processo para a preparação dos mesmos - Google Patents

ésteres de ácido de piridin-2-il sulfanila e processo para a preparação dos mesmos

Info

Publication number
BR112013001244A2
BR112013001244A2 BR112013001244A BR112013001244A BR112013001244A2 BR 112013001244 A2 BR112013001244 A2 BR 112013001244A2 BR 112013001244 A BR112013001244 A BR 112013001244A BR 112013001244 A BR112013001244 A BR 112013001244A BR 112013001244 A2 BR112013001244 A2 BR 112013001244A2
Authority
BR
Brazil
Prior art keywords
pyridin
sulfanyl
acid esters
inflammatory
preparation
Prior art date
Application number
BR112013001244A
Other languages
English (en)
Inventor
Balaram Ghosh
Dilip Chandra Bora
Jadab Chandra Sarma
Paruchuri Gangadhar Rao
Sakshi Balwani
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Publication of BR112013001244A2 publication Critical patent/BR112013001244A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

ésteres de ácido de piridin-2-il sulfanila e processo para a preparação dos mesmos. a presente invenção refere-se aos compostos de éster de ácido de piridin-3-il sulfanila tendo propriedades anti-inflamatórias. a presente invenção particularmente se refere aos novos ésteres de ácido heterocíclico anti-inflamatórios de piridin-2-il sulfanila tendo a estrutura de fórmula geral 1 que foram analisados quanto a sua atividade anti-inflamatória com respeito à inibição de adesão de neutrófilos, isolados do sangue periférico humano, na superfície de células endoteliais de veia umbilical humana (huvec) como um resultado de inibição da expressão estimulada por citocina de icam-1 de molécula de adesão celular. o composto rs-z, 3-pentil éster de ácido (piridin-2-il-sulfanil)-propiônico (estrutura 1a, r~ 1~ = h, r~ 2~ = h, r~ 3~ = ch~ 2~cooc~ 5~h~ 11~) foi descoberto ser mais eficaz quanto à inibição de adesão de neutrófilo e icam-1 e foi descoberto eficazmente aliviar a inflamação mediada por infiltração de leucócito excessiva que induz a distúrbios inflamatórios ou condições similares, tais como lesão pulmonar aguda e síndrome da angústia respiratória aguda em camundongos.
BR112013001244A 2010-07-20 2011-07-20 ésteres de ácido de piridin-2-il sulfanila e processo para a preparação dos mesmos BR112013001244A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1691DE2010 2010-07-20
PCT/IN2011/000477 WO2012011123A1 (en) 2010-07-20 2011-07-20 Pyridin- 2 - yl sulfanyl acid esters and process for the preparation thereof

Publications (1)

Publication Number Publication Date
BR112013001244A2 true BR112013001244A2 (pt) 2016-05-17

Family

ID=44645766

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001244A BR112013001244A2 (pt) 2010-07-20 2011-07-20 ésteres de ácido de piridin-2-il sulfanila e processo para a preparação dos mesmos

Country Status (8)

Country Link
US (1) US8680288B2 (pt)
EP (1) EP2595957B1 (pt)
CN (1) CN103003242B (pt)
AU (1) AU2011281132B2 (pt)
BR (1) BR112013001244A2 (pt)
CA (1) CA2805098C (pt)
NZ (1) NZ604835A (pt)
WO (1) WO2012011123A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105745266B (zh) * 2013-11-26 2019-05-17 住友化学株式会社 橡胶组合物及硫化助剂
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4β7インテグリンの阻害のための化合物
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ, インコーポレイテッド アルファ4ベータ7インテグリン阻害剤としてのイミダゾピリジン誘導体
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4ベータ7インテグリンの阻害のための化合物
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6369696A (en) * 1995-07-17 1997-02-18 Fuji Photo Film Co., Ltd. Benzimidazole compounds
US6777432B1 (en) * 2001-09-04 2004-08-17 Darwin Molecular Corporation Pharmaceutical uses and synthesis of nicotinamides
FR2899899A1 (fr) * 2006-04-14 2007-10-19 Sanofi Aventis Sa Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
US20130131350A1 (en) 2013-05-23
AU2011281132A1 (en) 2013-01-17
EP2595957B1 (en) 2014-08-13
CA2805098C (en) 2015-09-15
CN103003242B (zh) 2015-04-22
CN103003242A (zh) 2013-03-27
AU2011281132B2 (en) 2014-01-30
CA2805098A1 (en) 2012-01-26
NZ604835A (en) 2014-05-30
WO2012011123A1 (en) 2012-01-26
EP2595957A1 (en) 2013-05-29
US8680288B2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
BR112013001244A2 (pt) ésteres de ácido de piridin-2-il sulfanila e processo para a preparação dos mesmos
Zhang et al. JMJD3 in the regulation of human diseases
BR112012027062A2 (pt) composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BR112012014899A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
BR112013006932A2 (pt) composto composição farmacêutica e processo para preparar um composto
BR112012010762A2 (pt) inibidores de prolil hidroxilalse
EA200802288A1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
EA201590624A1 (ru) Циклические эфиры пиразол-4-ил-гетероциклил-карбоксамидных соединений и способы их применения
BR112012020922A2 (pt) compostos de pirrolopirimidina como inibidores de cdk4/6.
BR112014013661A2 (pt) Derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
BR112015014701A2 (pt) derivados de benzimidazol como inibidores de quinase
BR112015012454A8 (pt) compostos inibidores de atr quinase, seu uso, composição farmacêutica compreendendo os mesmos, seus intermediários e método de preparação
BR112014012129A8 (pt) inibidores heterocíclicos de glutaminase
EP3363797A8 (en) Oral dosage form of apoptosis signal-regulating kinase inhibitors
MA33838B1 (fr) Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase
BR112015007832A2 (pt) adesivos e métodos relacionados
ME01285A (me) Derivati dioksa-bicikl0[3.2.1]oktan-2,3,4-triola
Henriet et al. A jasmonic acid derivative improves skin healing and induces changes in proteoglycan expression and glycosaminoglycan structure
NZ603935A (en) Novel immunomodulator and anti inflammatory compounds
Zhi et al. Characteristic microRNA expression induced by δ-opioid receptor activation in the rat liver under prolonged hypoxia
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
BRPI0511424A (pt) composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para a preparação de um composto
BR112014013958A2 (pt) ácidos piperidinila naftilacéticos
BR112014001518A2 (pt) derivados de ácido 3-heteroaroilamino-propiônico e seus usos como produtos farmacêuticos

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)